Expert Interview
A Second View: Looking at the results from Anavex Life Sciences' Phase IIb/III Trial of Blarcamesine in Alzheimer's Disease
Ticker(s): AVXL, LLY, BIIBInstitution: Northwell Health
- Assistant Professor, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.
- Currently treats >75 patients with Alzheimer's Disease.
- Extensive focus on neuro-rehabilitation; leads the Parkinson’s rehab program at Glen Cove Hospital.
Please describe your background and practice setting
Added By: ben_adminExplain how your standard of care has evolved since the FDA approval of Leqembi and Kisunla
Added By: ben_adminWhat is your high level opinion on the data to date on Blarcamesine?
Added By: ben_adminWhat is your opinion on the different mechanism of action presented by Anavex's Blarcamesine, specifically regarding SIGMAR1 activation and its potential for neuroprotection?
How do the baseline demographics and genetic components (such as APOE genotype) in Anavex's trial compare to real-world patient populations, and how important is genetic testing for patient selection?
What is your assessment of the co-primary endpoints, particularly the significance of the ADAS-Cog 13 results, and the lack of significance in the ADLs?
Given the safety profile and delivery method of Blarcamesine, how would you rank your overall excitement for this treatment on a scale of 1 to 10?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
